We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+34.93%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$132M
AUM Growth
+$31.8M
Cap. Flow
+$10.8M
Cap. Flow %
8.18%
Top 10 Hldgs %
55.55%
Holding
79
New
8
Increased
18
Reduced
14
Closed
10

Top Buys

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$5.63M
2
CMPX icon
Compass Therapeutics
CMPX
+$2.76M
3
FOLD
Amicus Therapeutics
FOLD
+$1.6M
4
BCYC
Bicycle Therapeutics
BCYC
+$1.16M
5
GPCR icon
Structure Therapeutics
GPCR
+$837K

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$1.13M
2
ELUT icon
Elutia
ELUT
+$830K
3
HROW icon
Harrow
HROW
+$753K
4
AXGN icon
Axogen
AXGN
+$608K
5
XNCR icon
Xencor
XNCR
+$550K

Sector Composition

Rank Sector Weight
1 Healthcare 76.79%
2 Technology 17.82%
3 Energy 4.7%
4 Materials 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVCR icon
26
NovoCure
NVCR
$2.04B
$1.32M 1%
102,100
+1,100
+1% +$14.7K
UTHR icon
27
United Therapeutics
UTHR
$26.3B
$1.26M 0.95%
3,000
-1,250
-29% -$420K
IMNM icon
28
Immunome
IMNM
$2.52B
$1.23M 0.93%
105,000
+45,000
+75% +$448K
MASI
29
DELISTED
Masimo
MASI
$1.22M 0.92%
8,280
– –
BCYC
30
Bicycle Therapeutics
BCYC
$270M
$1.19M 0.9%
+154,000
New +$1.16M
TMCI icon
31
Treace Medical Concepts
TMCI
$259M
$1.19M 0.9%
176,947
– –
KNSA icon
32
Kiniksa Pharmaceuticals
KNSA
$4.83B
$1.16M 0.88%
30,000
– –
OM icon
33
Outset Medical
OM
$74.9M
$1.11M 0.84%
78,584
+44,000
+127% +$686K
INBX icon
34
Inhibrx
INBX
$1.2B
$1.07M 0.81%
31,698
-412
-1% -$10.1K
DCGO icon
35
DocGo
DCGO
$58.9M
$1.04M 0.78%
764,062
– –
NTLA icon
36
Intellia Therapeutics
NTLA
$1.5B
$1.04M 0.78%
60,000
– –
TVTX icon
37
Travere Therapeutics
TVTX
$5.33B
$1.03M 0.78%
43,060
-59,940
-58% -$1.13M
PHAT icon
38
Phathom Pharmaceuticals
PHAT
$912M
$1M 0.76%
85,000
+60,000
+240% +$619K
SRRK icon
39
Scholar Rock
SRRK
$5.71B
$968K 0.73%
26,000
+10,000
+63% +$350K
XENE icon
40
Xenon Pharmaceuticals
XENE
$6.32B
$843K 0.64%
21,000
– –
KALV
41
DELISTED
KalVista Pharmaceuticals
KALV
$816K 0.62%
67,000
– –
HALO icon
42
Halozyme
HALO
$9.72B
$741K 0.56%
10,100
+100
+1% +$6.64K
AXSM icon
43
Axsome Therapeutics
AXSM
$12.4B
$729K 0.55%
6,000
– –
FCX icon
44
Freeport-McMoran
FCX
$90B
$708K 0.53%
18,044
+11
+0.1% +$477
RARE icon
45
Ultragenyx Pharmaceutical
RARE
$2.65B
$662K 0.5%
22,000
+4,000
+22% +$120K
PACB icon
46
Pacific Biosciences
PACB
$422M
$640K 0.48%
500,000
+100,000
+25% +$135K
APGE icon
47
Apogee Therapeutics
APGE
$10.2B
$636K 0.48%
16,000
– –
ELUT icon
48
Elutia
ELUT
$41.1M
$633K 0.48%
711,175
-447,884
-39% -$830K
VYGR icon
49
Voyager Therapeutics
VYGR
$187M
$630K 0.48%
+134,918
New +$488K
ATEC icon
50
Alphatec Holdings
ATEC
$1.27B
$480K 0.36%
33,000
– –
1
2
3 4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Birchview Capital held 79 positions worth $132M, up 32% from $101M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Birchview Capital deployed $10.8M of net new capital in Q3 2025, opening 8 new positions and adding to 18 existing holdings. Its largest new stake was Compass Therapeutics: 872,938 shares worth $3.06M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 79% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $1.13M trimmed.

  • Birchview Capital's largest Q3 2025 buy was Compass Therapeutics: 872,938 shares worth $3.06M.
  • Birchview Capital added most to KLA in Q3 2025, an estimated $5.63M increase.
  • Birchview Capital's biggest Q3 2025 reduction was Travere Therapeutics, cutting an estimated $1.13M.
  • Birchview Capital fully exited Xencor in Q3 2025, selling an estimated $550K.
  • Birchview Capital's ten largest holdings make up 56% of its $132M portfolio in Q3 2025.
  • Birchview Capital opened 8 new positions and closed 10 in Q3 2025.
  • Birchview Capital's portfolio value rose 32% quarter-over-quarter to $132M.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.